ReviewDrug safety2021

Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.

Philip G Conaghan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.